Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haplo-identical stem cell and cord blood co-infusion in very high-risk hematologic malignancies
NL-OMON22000Phase 2Not yet recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Nov 2011
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of umbilical cord blood stem cells in hematopoietic malignancies, acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and 4 more, sponsored by University Medical Center Utrecht. Primary endpoints: Transplantation-related mortality and Anti-tumor response mechanism. Planned start Nov 2011; status: not yet recruiting.
02
Drugs
umbilical cord blood stem cells
03
Conditions
hematopoietic malignanciesacute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NL-OMON22000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON22000.